SHORT MINI-FUTURE - GENMAB | Delayed Deutsche Boerse AG 08:31:09 27/05/2024 pm IST | ||
| 31.84 EUR | -0.34% |
|
| Current month | -0.22% | ||
| 1 month | +0.92% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
More news
| Date | Price | Change |
|---|---|---|
| 27/24/27 | 31.84 | -0.34% |
| 24/24/24 | 31.95 | +3.06% |
| 23/24/23 | 31 | +1.64% |
| 22/24/22 | 30.5 | -1.90% |
| 21/24/21 | 31.09 | +1.53% |
Delayed Quote Deutsche Boerse AG
Last update May 27, 2024 at 08:31 pm IST
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GENMAB A/S |
| Issuer | 
Vontobel
|
| WKN | VU0EM3 |
| ISIN | DE000VU0EM33 |
| Date issued | 01/12/2022 |
| Strike | 4,340 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 15.75 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 33.6 € |
|---|---|
| Lowest since issue | 13.95 € |
| Spread | 0.48 € |
| Spread % | 1.49% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
1,926
DKK
Average target price
2,466
DKK
Spread / Average Target
+27.99%
- Stock Market
- Certificates
- Certificat
